AbbVie Inc. $ABBV Stock: Robeco Institutional Asset Management B.V. Grows Position

Robeco Institutional Asset Management B.V. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.0% in the third quarter, Holdings Channel reports. The firm owned 3,706,187 shares of the company’s stock after buying an additional 141,068 shares during the quarter. AbbVie accounts for 1.1% of Robeco Institutional Asset Management B.V.’s investment portfolio, making the stock its 14th biggest holding. Robeco Institutional Asset Management B.V.’s holdings in AbbVie were worth $969,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Sensible Money LLC raised its stake in shares of AbbVie by 24.6% during the third quarter. Sensible Money LLC now owns 1,177 shares of the company’s stock worth $308,000 after purchasing an additional 232 shares during the last quarter. Zullo Investment Group Inc. grew its position in AbbVie by 1.3% in the 3rd quarter. Zullo Investment Group Inc. now owns 5,613 shares of the company’s stock valued at $1,469,000 after buying an additional 71 shares during the last quarter. Petredis Investment Advisors LLC grew its position in AbbVie by 0.5% in the 3rd quarter. Petredis Investment Advisors LLC now owns 21,495 shares of the company’s stock valued at $5,623,000 after buying an additional 113 shares during the last quarter. Revisor Wealth Management LLC increased its stake in AbbVie by 4.7% in the 3rd quarter. Revisor Wealth Management LLC now owns 3,559 shares of the company’s stock valued at $1,017,000 after buying an additional 160 shares during the period. Finally, Briaud Financial Planning Inc acquired a new position in AbbVie in the 3rd quarter valued at $204,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin α4β7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466
• Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise
• Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals
• Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren
• Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada reiterated an “outperform” rating and set a $280.00 price target on shares of AbbVie in a research note on Tuesday, October 13th. Morgan Stanley increased their price target on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Cantor Fitzgerald raised their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Finally, HSBC raised their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Stock Performance

AbbVie stock opened at $288.66 on Wednesday. The firm has a market capitalization of $510.01 billion, a price-to-earnings ratio of 81.54, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40. The stock’s fifty day moving average is $264.22 and its two-hundred day moving average is $240.39.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by company insiders.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.